Comparable stake leader
BlackRock, Inc.
SEC ownership of Vir Biotechnology, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001706431.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- VIR on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001706431
- Issuer location
- San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Vir Biotechnology, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 11%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 11%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
11%
ARCH Venture Fund IX, L.P.
8.5%
VANGUARD PORTFOLIO MANAGEMENT LLC
6.8%
SB INVESTMENT ADVISERS (UK) LTD
6.5%
STATE STREET CORP
5.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
11%
from 13D/G
|
$210,711,705
20,678,283 shares
|
— | 30 Jun 2026 |
| ARCH Venture Fund IX, L.P. |
13D/G
Robert Nelsen
|
8.5%
|
$101,645,627
13,534,704 shares
|
$0 | 27 Feb 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
13F
Vanguard Portfolio Management · Company
|
6.8%
|
$120,512,152
11,554,377 shares
|
+$23,959,191 | 30 Jun 2026 |
| SB INVESTMENT ADVISERS (UK) LTD |
13D/G
13F
SB Investment Advisers (UK) Limited · Company
|
6.5%
|
$118,567,847
10,948,093 shares
|
-$23,489,014 | 31 Mar 2026 |
| STATE STREET CORP |
13D/G
13F
STATE STREET CORPORATION · Company
|
5.9%
|
$103,926,095
9,964,151 shares
|
$0 | 30 Jun 2026 |
| SVF Endurance (Cayman) Ltd |
3/4/5
10%+ Owner
|
8.1%
|
$82,134,660
13,728,924 shares
|
-$17,847,707 | 01 Dec 2025 |
| Vicki L. Sato |
3/4/5
Director
|
0.64%
|
$10,858,643
1,078,391 shares
mixed-class rows
|
-$1,727,757 | 01 May 2026 |
| ARCH Venture Management, LLC |
13F
Company
|
7.5%
|
$129,353,521
12,694,163 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$21,001,891.
Buys
$0
Insiders: 0
Sells
$21,001,891
Insiders: 8
Net
-$21,001,891
Shares: -3,337,061
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 3,337,061
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 127,849 | $0 | $1,189,138 | -$1,189,138 |
| 6-9 | 0 | 177,546 | $0 | $1,522,440 | -$1,522,440 |
| 9-12 | 0 | 3,031,666 | $0 | $18,290,313 | -$18,290,313 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 28 reporting-owner rows connected to Vir Biotechnology, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
28
Largest Forms 3/4/5 holder
SVF Endurance (Cayman) Ltd
Net 12M change
-$21,001,890
Latest report
11 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd | 10%+ Owner | $82,134,660 | -$17,847,707 | -18% | Filing P/S | 01 Dec 2025 |
| Vicki L. Sato | Director | $10,858,643 | -$1,727,757 | -14% | Mixed | 01 May 2026 |
| Marianne de Backer | President and CEO, Director | $9,705,716 | -$946,964 | -8.9% | Mixed | 29 Apr 2026 |
| George A. Scangos | Director | $8,326,163 | Mixed | 24 Feb 2025 | ||
| Robert Nelsen | Director | $5,869,727 | Mixed | 30 May 2024 | ||
| Robert J. More | Director | $5,716,338 | Mixed | 11 Aug 2026 | ||
| Phillip Pang | EVP & Chief Medical Officer | $2,512,515 | Filing P/S | 22 Feb 2024 | ||
| Jason O'Byrne | EVP & Chief Financial Officer | $1,637,971 | -$68,927 | -4% | Mixed | 20 Mar 2026 |
| Mark Eisner | EVP and Chief Medical Officer | $1,634,915 | -$49,524 | -2.9% | Mixed | 24 Feb 2026 |
| Vanina de Verneuil | EVP, General Counsel, Corp Sec | $1,216,583 | -$217,684 | -15% | Mixed | 24 Feb 2026 |
| Ann M. Hanly | EVP & Chief Technology Officer | $1,214,015 | Mixed | 24 Feb 2025 | ||
| Sung Lee | EVP & Chief Financial Officer | $1,116,015 | Mixed | 27 Mar 2024 | ||
| Brent Sabatini | SVP, Chief Accounting Officer | $646,173 | -$113,087 | -15% | Mixed | 01 Jun 2026 |
| Herbert Virgin | EVP, Research & CSO | $593,511 | Mixed | 09 Aug 2022 | ||
| Charles Elliott Sigal | Director | $470,741 | Mixed | 27 May 2026 | ||
| Jeffrey S. Hatfield | Director | $381,141 | Mixed | 27 May 2026 | ||
| Howard Horn | Cfo | $352,989 | Mixed | 23 Feb 2023 | ||
| Ramy Farid | Director | $311,200 | Mixed | 27 May 2026 | ||
| Norbert W. Bischofberger | Director | $311,199 | Mixed | 27 May 2026 | ||
| Phillip A. Sharp | Director | $271,838 | Mixed | 22 May 2023 |
Recent insider transactions for Vir Biotechnology, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert J. More | VIR | Common Stock | Other | 1.57% | 8,000 | 517,917 | 11 Aug 2026 | See footnote | ||
| Robert J. More | VIR | Common Stock | Other | -16.4% | -8,000 | 40,656 | 11 Aug 2026 | Direct | ||
| Timothy Coughlin | VIR | Common Stock | Award | 16,000 | 16,000 | 09 Jun 2026 | Direct | |||
| Timothy Coughlin | VIR | Stock Option (Right to Buy) | Award | 32,000 | 16,000 | 09 Jun 2026 | Direct | |||
| Janet Napolitano | VIR | Common Stock | Sale | -13.1% | $30,240 | $9.45 | -3,200 | 21,216 | 01 Jun 2026 | Direct |
| Brent Sabatini | VIR | Common Stock | Sale | -0.61% | $3,582 | $9.45 | -379 | 61,902 | 01 Jun 2026 | Direct |
| Charles Elliott Sigal | VIR | Common Stock | Award | 25.2% | 8,000 | 39,806 | 27 May 2026 | Direct | ||
| Charles Elliott Sigal | VIR | Stock Option (Right to Buy) | Award | 16,000 | 16,000 | 27 May 2026 | Direct | |||
| Janet Napolitano | VIR | Common Stock | Award | 48.7% | 8,000 | 24,416 | 27 May 2026 | Direct | ||
| Janet Napolitano | VIR | Stock Option (Right to Buy) | Award | 16,000 | 16,000 | 27 May 2026 | Direct | |||
| Robert J. More | VIR | Common Stock | Award | 19.7% | 8,000 | 48,656 | 27 May 2026 | Direct | ||
| Robert J. More | VIR | Stock Option (Right to Buy) | Award | 16,000 | 16,000 | 27 May 2026 | Direct | |||
| Jeffrey S. Hatfield | VIR | Common Stock | Award | 25.2% | 8,000 | 39,806 | 27 May 2026 | Direct | ||
| Jeffrey S. Hatfield | VIR | Stock Option (Right to Buy) | Award | 16,000 | 16,000 | 27 May 2026 | Direct | |||
| Ramy Farid | VIR | Common Stock | Award | 33.3% | 8,000 | 32,000 | 27 May 2026 | Direct | ||
| Ramy Farid | VIR | Stock Option (Right to Buy) | Award | 16,000 | 16,000 | 27 May 2026 | Direct | |||
| Norbert W. Bischofberger | VIR | Common Stock | Award | 60% | 8,000 | 21,333 | 27 May 2026 | Direct | ||
| Norbert W. Bischofberger | VIR | Stock Option (Right to Buy) | Award | 16,000 | 16,000 | 27 May 2026 | Direct | |||
| Vicki L. Sato | VIR | Common Stock | Sale | -2% | $221,025 | $10.05 | -22,000 | 1,078,391 | 01 May 2026 | Direct |
| Marianne de Backer | VIR | Common Stock | Other | 439.6% | 233,532 | 286,650 | 29 Apr 2026 | See Footnote | ||
| Marianne de Backer | VIR | Common Stock | Other | -24.6% | -233,532 | 714,613 | 29 Apr 2026 | Direct | ||
| Marianne de Backer | VIR | Common Stock | Sale | -7.11% | $664,350 | $9.16 | -72,559 | 948,145 | 06 Apr 2026 | Direct |
| Vicki L. Sato | VIR | Common Stock | Sale | -1.96% | $199,617 | $9.07 | -22,000 | 1,100,391 | 01 Apr 2026 | Direct |
| Brent Sabatini | VIR | Common Stock | Sale | -11.1% | $70,324 | $9.12 | -7,711 | 61,902 | 23 Mar 2026 | Direct |
| Jason O'Byrne | VIR | Common Stock | Other | 2,500 | 2,500 | 20 Mar 2026 | See Footnote | |||
| Jason O'Byrne | VIR | Common Stock | Other | -1.54% | -2,500 | 160,115 | 20 Mar 2026 | Direct | ||
| Vicki L. Sato | VIR | Common Stock | Sale | -1.92% | $209,181 | $9.51 | -22,000 | 1,122,391 | 02 Mar 2026 | Direct |
| Mark Eisner | VIR | Common Stock | Sale | -1.21% | $18,550 | $9.82 | -1,889 | 154,024 | 25 Feb 2026 | Direct |
| Vanina de Verneuil | VIR | Common Stock | Sale | -10.8% | $134,534 | $9.82 | -13,700 | 112,982 | 25 Feb 2026 | Direct |
| Vicki L. Sato | VIR | Common Stock | Sale | -3.57% | $413,366 | $9.75 | -42,377 | 1,144,391 | 24 Feb 2026 | Direct |
| Vicki L. Sato | VIR | Common Stock | Options Exercise | 3.7% | 42,377 | 1,186,768 | 24 Feb 2026 | Direct | ||
| Vicki L. Sato | VIR | Stock Option (Right to Buy) | Options Exercise | -100% | -42,377 | 0 | 24 Feb 2026 | Direct | ||
| Brent Sabatini | VIR | Common Stock | Sale | -2.01% | $13,632 | $9.53 | -1,430 | 69,613 | 24 Feb 2026 | Direct |
| Jason O'Byrne | VIR | Common Stock | Sale | -0.99% | $15,576 | $9.53 | -1,634 | 162,615 | 24 Feb 2026 | Direct |
| Mark Eisner | VIR | Common Stock | Sale | -1.03% | $15,405 | $9.53 | -1,616 | 155,913 | 24 Feb 2026 | Direct |
| Vanina de Verneuil | VIR | Common Stock | Sale | -2.4% | $29,713 | $9.53 | -3,117 | 126,682 | 24 Feb 2026 | Direct |
| Marianne de Backer | VIR | Common Stock | Sale | -1.43% | $140,720 | $9.53 | -14,762 | 1,020,704 | 24 Feb 2026 | Direct |
| Brent Sabatini | VIR | Common Stock | Sale | -2.51% | $13,631 | $7.45 | -1,829 | 71,043 | 23 Feb 2026 | Direct |
| Jason O'Byrne | VIR | Common Stock | Sale | -1.26% | $15,569 | $7.45 | -2,089 | 164,249 | 23 Feb 2026 | Direct |
| Mark Eisner | VIR | Common Stock | Sale | -1.31% | $15,569 | $7.45 | -2,089 | 157,529 | 23 Feb 2026 | Direct |
| Vanina de Verneuil | VIR | Common Stock | Sale | -3.31% | $33,128 | $7.45 | -4,445 | 129,799 | 23 Feb 2026 | Direct |
| Marianne de Backer | VIR | Common Stock | Sale | -1.81% | $141,894 | $7.45 | -19,039 | 1,035,466 | 23 Feb 2026 | Direct |
| Brent Sabatini | VIR | Common Stock | Award | 52.2% | 25,000 | 72,872 | 22 Feb 2026 | Direct | ||
| Brent Sabatini | VIR | Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 22 Feb 2026 | Direct | |||
| Jason O'Byrne | VIR | Common Stock | Award | 49.4% | 55,000 | 166,338 | 22 Feb 2026 | Direct | ||
| Jason O'Byrne | VIR | Stock Option (Right to Buy) | Award | 110,000 | 110,000 | 22 Feb 2026 | Direct | |||
| Mark Eisner | VIR | Common Stock | Award | 52.6% | 55,000 | 159,618 | 22 Feb 2026 | Direct | ||
| Mark Eisner | VIR | Stock Option (Right to Buy) | Award | 110,000 | 110,000 | 22 Feb 2026 | Direct | |||
| Vanina de Verneuil | VIR | Common Stock | Award | 69.4% | 55,000 | 134,244 | 22 Feb 2026 | Direct | ||
| Vanina de Verneuil | VIR | Stock Option (Right to Buy) | Award | 110,000 | 110,000 | 22 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.